Cannabis Science Inc, an emerging pharmaceutical cannabis company, announced that patent filings are expected for two of its key innovations.

"The Drug Development Team members recognize the importance of having our first cannabis-based medicine covered, not just by one patent, but by two," Dr Mary J Ruwart, vice president, Research & Development explained. "A competitor can sometimes engineer a way around a single patent. Patenting both the manufacturing process as well as the delivery system virtually guarantees that our product will be immune to 'invasion' by a competing company."

Cannabis Science CEO, Steve Kubby, is the inventor who will assign both of his patents to Cannabis Science. "Our new manufacturing process allows for the rapid and uniform harvesting of cannabis 'trichomes,' the part of the plant containing the active ingredient, THC," Kubby told potential investors today. "Just as the cotton gin made cotton harvesting economically feasible, our innovative process will revolutionize trichome harvesting."

"Having a creative mind like Steve Kubby's at the helm gives us a competitive advantage," Dr Robert Melamede, chief scientific officer commented. "The new manufacturing process is only the tip of the proverbial iceberg. The unique drug delivery system he has designed enhances the stability and uniform absorption of the active ingredient. We expect our first product to outshine the competition with rapid---and prolonged---blood levels of THC."

Cannabis Science management has authorized expenditures for patents; the two described above will be the company's first official filings. "Naturally, Cannabis Science will use both of its discoveries for its own drug production," chief financial officer, Richard Cowan said. "However, other firms will likely want to license these inventions for their own use as well. Cannabis Science will be able to supply other companies with superior trichome preparations or provide our unique drug delivery systems for other pharmaceutical preparations. The entire industry, the American public, and, of course, Cannabis Science and its investors, will reap the benefits."

Cannabis Science is at the forefront of medical marijuana research and development. The company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products.